Ownership changes in the pharmaceutical industry: understanding the 2023 pharma mergers and acquisitions landscape of Europe [0.03%]
制药行业的所有权变化：理解2023年欧洲医药并购格局
Daniel Fabian,Claudia Wild
Daniel Fabian
Background: The pharmaceutical industry is experiencing significant transformations driven by mergers and acquisitions (M&A), leading to complex debates regarding their impact on innovation. This study examines the intric...
Determinants, Models, performances, and strategies of supply chain to address medicine stockouts in primary health care: a scoping review [0.03%]
针对初级卫生保健药品缺货的供应链决定因素、模型、绩效和策略：一项纲要综述
Fina Aryani,Dika P Destiani,Satibi Satibi et al.
Fina Aryani et al.
Background: Medicine stockouts (MSOs) remain a significant challenge to delivering quality health services in primary care, primarily due to inefficiencies in Medicine Supply Chain Management (MSCM). This study reviewed e...
Developing a framework to assess off-patent medicines policies in Latin America and the Caribbean [0.03%]
在拉丁美洲和加勒比地区制定评估off-patent药物政策的框架
Jaime Espín,Santiago Palacio-Ciro,Ana Amaris et al.
Jaime Espín et al.
Background: Countries in Latin America and the Caribbean (LAC) often lack a systematic approach to assessing the maturity and effectiveness of their policies for promoting off-patent (generic and biosimilar) medicines. Cu...
Asthma and chronic obstructive disease overlap (ACO), a systematic review of prevalence and co-morbidity factors based on diagnostic criteria [0.03%]
基于诊断标准的哮喘与慢性阻塞性疾病重叠综合征(ACO)患病率及共病因素系统评价
Farha Sayyeda,Irfhan Ali Hyder Ali,Sabariah Noor Harun et al.
Farha Sayyeda et al.
Background: Asthma and chronic obstructive pulmonary disease (COPD) overlap (ACO) is a complex pathological condition involving features of both asthma and COPD. While the individual diagnoses of asthma and COPD are well ...
The prevalence and predictor factors of urinary tract infection in type 2 diabetes mellitus patients receiving SGLT2 inhibitors in Qatar: A retrospective cohort study [0.03%]
卡塔尔2型糖尿病患者使用SGLT2抑制剂的尿路感染患病率及预测因素：一项回顾性队列研究
Shahad H Alhefel,Binny Thomas,Mohamed Sherbash et al.
Shahad H Alhefel et al.
Background and aims: Urinary Tract Infections (UTIs) are common in Type 2 Diabetes Mellitus (T2DM) patients. While Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors improve T2DM treatment by lowering blood glucose, they may increase UTI ri...
Quantifying public and private investment in biopharmaceutical R&D: a study of seven middle- and high-income countries [0.03%]
量化生物制药研发的公共和私人投资：七国中高收入国家的研究报告
Annabelle Fowler,Anupama Tantri,Julia Spencer et al.
Annabelle Fowler et al.
Background: Fostering biopharmaceutical R&D has been a key element of industrial and innovation policy worldwide. Typically, this requires complementary investments from the public and private sectors. However, there is l...
Community pharmacy based point-of-care testing for early detection of undiagnosed type 2 diabetes mellitus: a study protocol [0.03%]
社区药房基于点对检测以早期发现未诊断的二型糖尿病：一项研究方案
Khaled Alshorman,Rabia Hussain
Khaled Alshorman
Background: Type 2 diabetes mellitus (T2DM) remains substantially underdiagnosed worldwide, contributing to delayed treatment and increased risk of long-term complications. Community pharmacies are highly accessible healt...
Impact of PharmaTE trial on glycemic control, diabetes knowledge, medication adherence, and quality of life in type 2 diabetes patients: a mixed-methods study protocol [0.03%]
PharmaTE试验对2型糖尿病患者血糖控制、糖尿病知识、依从性和生活质量的影响：一项混合方法研究方案
Nour Aymn Ahmad,Rabia Hussain
Nour Aymn Ahmad
Background: Diabetes mellitus (DM) is a significant public health issue that requires lifelong management. Effective management requires a comprehensive approach integrating technology and clinical pharmacists into the he...
Effectiveness and safety of ceftazidime/avibactam versus polymyxin B in liver transplant recipients with carbapenem-resistant organism infections: a real-world cohort study [0.03%]
头孢他啶/阿维巴坦与多粘菌素B治疗碳青霉烯耐药病原体感染肝移植受者的疗效和安全性：真实世界队列研究
Weiwei Zhang,Chuanlin Chen,Desheng Li et al.
Weiwei Zhang et al.
Background: Treatment options for carbapenem-resistant organism (CRO) infections remain limited, with ceftazidime/avibactam (CAZ/AVI) and polymyxin B (PMB) being the main therapeutic choices. However, comparative evidence...
Enhancing access to treatment and programmes for viral hepatitis in an endemic country: a narrative review of literature from 2000 to 2025 (Mongolia) [0.03%]
增强获得治疗和计划以防治流行国家的病毒性肝炎：2000年至2025年蒙古文献综述
Gantuya Dorj,Undram Lkhagva,Gereltuya Dorj et al.
Gantuya Dorj et al.
Background: Mongolia continues to experience the world's highest incidence of hepatocellular carcinoma (HCC), driven by chronic hepatitis B (HBV) and hepatitis C (HCV) infections. In response, the Mongolian Government has...